RA
HBIO icon

Royce & Associates’s Harvard Bioscience HBIO Stock Holding History

Royce & Associates’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-177,789
Closed -$1.01M – 811
2025
Q1 		$1.01M Sell
177,789
-18,722
-10% -$240K 0.01% 667
2024
Q4 		$4.15M Buy
196,511
+51,366
+35% +$1.18M 0.04% 522
2024
Q3 		$3.9M Buy
145,145
+1,000
+0.7% +$29.5K 0.04% 520
2024
Q2 		$4.11M Buy
144,145
+9,267
+7% +$325K 0.04% 513
2024
Q1 		$5.72M Sell
134,878
-10,205
-7% -$459K 0.05% 465
2023
Q4 		$7.76M Buy
145,083
+4,020
+3% +$181K 0.07% 386
2023
Q3 		$6.07M Buy
141,063
+980
+0.7% +$45.2K 0.06% 430
2023
Q2 		$7.69M Sell
140,083
-3,835
-3% -$210K 0.07% 386
2023
Q1 		$6.04M Buy
143,918
+1,432
+1% +$42.5K 0.06% 446
2022
Q4 		$3.95M Sell
142,486
-7,340
-5% -$181K 0.04% 527
2022
Q3 		$3.84M Sell
149,826
-12,200
-8% -$404K 0.04% 503
2022
Q2 		$5.83M Sell
162,026
-6,570
-4% -$297K 0.06% 431
2022
Q1 		$10.5M Sell
168,596
-12,720
-7% -$752K 0.09% 344
2021
Q4 		$12.8M Sell
181,316
-516
-0.3% -$36.7K 0.1% 337
2021
Q3 		$12.7M Sell
181,832
-19,563
-10% -$1.56M 0.09% 343
2021
Q2 		$16.8M Buy
201,395
+9,600
+5% +$679K 0.12% 306
2021
Q1 		$10.5M Buy
191,795
+25,235
+15% +$1.23M 0.07% 436
2020
Q4 		$7.14M Buy
166,560
+7,187
+5% +$268K 0.06% 469
2020
Q3 		$4.8M Sell
159,373
-28,087
-15% -$945K 0.05% 481
2020
Q2 		$5.81M Buy
187,460
+19,360
+12% +$522K 0.06% 420
2020
Q1 		$3.71M Buy
168,100
+3,000
+2% +$81.3K 0.05% 457
2019
Q4 		$5.04M Sell
165,100
-21,640
-12% -$623K 0.05% 491
2019
Q3 		$5.74M Buy
186,740
+3,760
+2% +$93.4K 0.05% 452
2019
Q2 		$3.66M Buy
182,980
+9,960
+6% +$292K 0.03% 567
2019
Q1 		$7.46M Hold
173,020
– – 0.06% 403
2018
Q4 		$5.5M Buy
173,020
+13,050
+8% +$514K 0.05% 477
2018
Q3 		$8.4M Buy
159,970
+3,470
+2% +$195K 0.06% 450
2018
Q2 		$8.37M Buy
156,500
+27,031
+21% +$1.38M 0.06% 446
2018
Q1 		$6.47M Sell
129,469
-20,241
-14% -$907K 0.05% 493
2017
Q4 		$4.94M Sell
149,710
-6,050
-4% -$204K 0.03% 589
2017
Q3 		$5.84M Hold
155,760
– – 0.04% 534
2017
Q2 		$3.97M Hold
155,760
– – 0.03% 660
2017
Q1 		$4.05M Buy
155,760
+4,400
+3% +$127K 0.03% 647
2016
Q4 		$4.62M Sell
151,360
-14,740
-9% -$375K 0.03% 600
2016
Q3 		$4.52M Buy
166,100
+11,500
+7% +$319K 0.03% 623
2016
Q2 		$4.42M Hold
154,600
– – 0.03% 624
2016
Q1 		$4.67M Buy
154,600
+22,500
+17% +$638K 0.03% 627
2015
Q4 		$4.58M Sell
132,100
-60
-0% -$2.05K 0.03% 639
2015
Q3 		$5M Buy
132,160
+140
+0.1% +$6.51K 0.03% 645
2015
Q2 		$7.53M Buy
132,020
+53,540
+68% +$3.05M 0.03% 634
2015
Q1 		$4.57M Buy
78,480
+1,000
+1% +$53.7K 0.02% 766
2014
Q4 		$4.39M Hold
77,480
– – 0.02% 809
2014
Q3 		$3.17M Buy
77,480
+770
+1% +$35.4K 0.01% 912
2014
Q2 		$3.49M Hold
76,710
– – 0.01% 939
2014
Q1 		$3.64M Hold
76,710
– – 0.01% 946
2013
Q4 		$3.6M Sell
76,710
-24,470
-24% -$1.07M 0.01% 959
2013
Q3 		$4.04M Hold
101,180
– – 0.01% 903
2013
Q2 		$3.63M Buy
+101,180
New +$3.87M 0.01% 930

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royce & Associates's HBIO Position: Q2 2025 in Review

Royce & Associates sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 177,789 shares — an estimated $1.01M sold.

Royce & Associates first reported a position in HBIO in Q2 2013 and held it in 48 quarters. The position peaked at $16.8M in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • Royce & Associates reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • Royce & Associates sold 177,789 Harvard Bioscience shares in Q2 2025, an estimated $1.01M.
  • Royce & Associates first reported a position in Harvard Bioscience in Q2 2013 and held it in 48 quarters.
  • Royce & Associates's Harvard Bioscience position peaked at $16.8M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Royce & Associates's 13F filing for Q2 2025, filed 11 Aug 2025.